8/1011 sources · 6 publishersUpdated Oct 28, 12:36 UTC
Boston Scientific reports Q3 2026 results and trims full‑year outlook after cyberattack
Boston Scientific posted third‑quarter 2026 net sales of $5.138 billion, GAAP EPS of $0.40 and adjusted EPS of $0.73. The company cut its full‑year 2026 sales growth outlook to about 4.25% reported (3.75% organic) and lowered adjusted FY EPS guidance to $3.16‑$3.18. It also forecast Q4 sales to fall 1%‑3% and adjusted Q4 EPS to $0.77‑$0.79, citing the August cyberattack’s impact on operations.
Why it matters
The reduced FY EPS guidance may pressure the stock and affect valuation models, as analysts had expected higher earnings. The weaker Q4 outlook signals near‑term revenue headwinds from the cyber incident.
Key facts
- 1Q3 2026 net sales were $5.138 billion, up 1.5% on a reported basis. prnewswire.com
- 2GAAP EPS for the quarter was $0.40 per share. prnewswire.com
- 3Adjusted EPS for the quarter was $0.73 per share. prnewswire.com
- 4Full‑year 2026 reported net‑sales growth is now estimated at 4.25%, organic growth at 3.75%. prnewswire.com
- 5Adjusted FY 2026 EPS guidance is $3.16‑$3.18. prnewswire.com
- 6Q4 2026 sales are expected to decline 1%‑3% versus the prior year period. prnewswire.com
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.